Sinotherapeutics Inc. A Cash Flow-to-Debt Ratio
Sinotherapeutics Inc. A cash flow-to-debt ratio. Sinotherapeutics Inc. A (688247) has a Cash Flow-to-Debt Ratio of 0.65x as of December 2025, meaning its operating cash flow of CN¥95.33 Million could theoretically repay 1% of its total liabilities (CN¥146.12 Million) in one year. Check 688247 cash flow quality score to evaluate the quality of earnings relative to operating cash generation.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Cash Flow-to-Debt Ratio of Sinotherapeutics Inc. A (2020–2025)
Cash flow-to-debt ratio of Sinotherapeutics Inc. A from 2020 to 2025. Historical debt coverage capacity for Sinotherapeutics Inc. A across 6 annual periods. Check Sinotherapeutics Inc. A total reinvestment intensity to assess the company's total reinvestment commitment from operating cash flow.
Sinotherapeutics Inc. A Cash Flow-to-Debt Ratio by Year (2020–2025)
Sinotherapeutics Inc. A cash flow-to-debt ratio by year from 2020 to 2025. Year-by-year debt coverage analysis for Sinotherapeutics Inc. A. For the full cash flow conversion analysis, see Sinotherapeutics Inc. A cash conversion from operations.
| Year | CF-to-Debt Ratio | Operating CF (CNY) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | 0.65x | CN¥95.33 Million | CN¥146.12 Million | ▼ -9.7% |
| 2024 | 0.72x | CN¥130.23 Million | CN¥180.30 Million | ▲ +743.7% |
| 2023 | 0.09x | CN¥12.96 Million | CN¥151.36 Million | ▼ -81.9% |
| 2022 | 0.47x | CN¥73.18 Million | CN¥155.05 Million | ▼ -48.0% |
| 2021 | 0.91x | CN¥145.77 Million | CN¥160.62 Million | ▼ -21.9% |
| 2020 | 1.16x | CN¥210.04 Million | CN¥180.76 Million | — |